CordenPharma is pleased to announce its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing
market. Dr. Christian Ewers
, Vice President Operations, CordenPharma,
announces the investment has already been initiated in CordenPharma Colorado
(Boulder, CO USA), and is expected to be complete before the end of the year. CordenPharma is in a unique position to enter this market segment due to their strong presence in Peptides, Lipids & Carbohydrates
for APIs and Drug Products. The expansion will broaden CordenPharma’s fully-integrated service offering, which has proven to be a very successful model in addressing customer time and cost saving needs by streamlining the manufacturing process.
“Based on the rich pipeline in the growing oligonucleotide field, this is a very logical move for CordenPharma within our current API and Drug Product manufacturing offerings. The expansion into the oligonucleotide market is a synergistic complement to our outstanding experience in the manufacture of synthetic lipids, peptides and carbohydrates, which are also used in oligonucleotide drug delivery” says Dr. Mimoun Ayoub
, Director, Peptides, Lipids, Carbohydrates & Injectables Platforms
, CordenPharma International
, President of CordenPharma Colorado
adds, “We are excited to start the initial phase to add oligonucleotide development and manufacturing to our existing broad capacities in peptides and highly potent APIs. Our strategy includes further investment down the road to accommodate much larger oligonucleotide volumes going forward. This will in turn allow us to better serve our customers’ needs for these innovative APIs.”
Read the Full Press Release Here.